ReviewArteriosclerosis, thrombosis, and vascular biology2009
New insights into cancer-associated thrombosis.
Review in Arteriosclerosis, thrombosis, and vascular biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 80 citations in OpenAlex.
- Trial
- The regulation of cancer-associated thrombosis by podoplanin.Thrombosis update · 2024Article
- Malignancy-associated ischemic stroke: Implications for diagnostic and therapeutic workup.CNS neuroscience & therapeutics · 2024Review
- Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data.Scientific reports · 2022Article
- Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Lung Cancer Patients Using Machine Learning.Frontiers in cardiovascular medicine · 2022Article
- Oral Squamous Cell Carcinoma Is Associated with a Low Thrombosis Risk Due to Storage Pool Deficiency in Platelets.Biomedicines · 2021Article
- Article
- Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms.Journal of stroke · 2020Review
- Review
- Protease-activated receptor 1 activation enhances doxorubicin-induced cardiotoxicity.Journal of molecular and cellular cardiology · 2018Article
- Pretreatment platelet count as a prognostic factor in patients with pancreatic cancer: a systematic review and meta-analysis.OncoTargets and therapy · 2018Article
- Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study.Ecancermedicalscience · 2018Article
- 14-3-3ζ regulates the mitochondrial respiratory reserve linked to platelet phosphatidylserine exposure and procoagulant function.Nature communications · 2016Article
- Impact of Transfusion on Cancer Growth and Outcome.Cancer growth and metastasis · 2016Review
- Cyclophosphamide, epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients.Molecular and clinical oncology · 2015Article
- Pre-operative thrombotic complications of neoadjuvant chemotherapy for breast cancer: Implications for immediate breast reconstruction.Annals of medicine and surgery (2012) · 2015Article
- Venous thromboembolism and lung cancer: a review.Multidisciplinary respiratory medicine · 2015Review
- Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.The Permanente journal · 2015Review
- A retrospective analysis of plasma D-dimer dynamic variation in terminal stage cancer patients: implications for disease progression.International journal of clinical and experimental medicine · 2014Article
- Thrombosis as a complication of central venous access in pediatric patients with malignancies: a 5-year single-center experience.BMC hematology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Venous thromboembolism (VTE) is an increasingly frequent complication of anticancer therapy. The underlying mechanisms are not completely understood, but are related in part to oncogene activation and tissue factor (TF) expression. Several risk factors have been identified including site and stage of cancer, patient comorbidities, and specific therapeutic agents. Candidate biomarkers such as blood counts, TF, and P-selectin have recently been identified. A risk model predictive of chemotherapy-associated VTE has been validated. Thromboprophylaxis with low molecular weight heparin (LMWH), unfractionated heparin (UFH), or fondaparinux is recommended for hospitalized medical and surgical cancer patients. Long-term anticoagulation with LMWH is safe and effective in reducing recurrent VTE in cancer. The role of thromboprophylaxis in ambulatory cancer patients receiving chemotherapy is an area of active investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.